Global Neuromyelitis Optica (NMO) / Neuromyelitis Optica Spectrum Disorder(NMOSD) Drug Market 2020 to 2029

                                          
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that can be fatal. NMOSD is a lifelong and debilitating autoimmune disorder of the central nervous system, often misdiagnosed as multiple sclerosis, that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis.

In patients with NMOSD, the body’s immune system mistakenly attacks healthy cells and proteins in the body, most often those in the optic nerves and spinal cord. Individuals with NMOSD typically have attacks of optic neuritis, which causes eye pain and vision loss.

Individuals also can have attacks resulting in transverse myelitis, which often causes numbness, weakness, or paralysis of the arms and legs, along with loss of bladder and bowel control. Most attacks occur in clusters, days to months to years apart, followed by partial recovery during periods of remission. Approximately 50% of patients with NMOSD have permanent visual impairment and paralysis caused by NMOSD attacks.

According to the National Institutes of Health, women are more often affected by NMOSD than men and African Americans are at greater risk of the disease than are Caucasians. Estimates vary, but NMOSD is thought to impact approximately 4,000 to 8,000 patients in the United States.

NMOSD can be associated with antibodies that bind to a protein called aquaporin-4 (AQP4). Binding of the anti-AQP4 antibody appears to activate other components of the immune system, causing inflammation and damage to the central nervous system. Multiple lines of evidence suggest that NMOSD is a B-cell-mediated disorder.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.

Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.

The global Neuromyelitis Optica Drug market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2020-2029.

This report focuses on Neuromyelitis Optica Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neuromyelitis Optica Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:


 	
Pfizer
 	
FRESENIUS
 	
TEVA
 	
SANDOZ
 	
Intas
 	
Gyjtrs
 	
NANG KUANG
 	
Tianjin Kingyork
 	
Baxter
 	
CSL
 	
Grifols
 	
Octapharma
 	
CBOP
 	
Viela Bio
 	
Genentech
 	
Alexion

Segment by Type

 	
Glucocorticoids
 	
Immunoglobulin

Segment by Application

 	
Acute attack
 	
Remission prophylactic treatment

Key Developments and Approval for Neuromyelitis optica (NMO) treatment

In Aug 2020, FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder. Its the first and only US FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks. This therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology. The approval was supported by one of the largest clinical trial programs undertaken for this rare disease.

The U.S. Food and Drug Administration (FDA) has approved Enspryng ™ (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).

Enspryng is a humanized monoclonal antibody and the only approved therapy for NMOSD designed to target and inhibit interleukin-6 (IL-6) receptor activity, believed to play a key role in the inflammation associated with NMOSD. The treatment was designed using novel recycling antibody technology, which, compared to conventional technology, allows for longer duration of antibody circulation and subcutaneous dosing every four weeks.

Enspryng is a humanized monoclonal antibody and the only approved therapy for NMOSD is designed to target and inhibit interleukin-6 (IL-6) receptor activity, believed to play a key role in the inflammation associated with NMOSD. The treatment was designed using novel recycling antibody technology, which, compared to conventional technology, allows for longer duration of antibody circulation and subcutaneous dosing every four weeks.

In Jun 2020, Viela Bio (Nasdaq:VIE) announced the U.S. Food and Drug Administration approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive) as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Uplizna is only the second approved treatment for the disorder.

UPLIZNA is an important new treatment option that provides prescribing physicians and patients living with NMOSD a therapy with proven efficacy, a favorable safety profile and a twice-a-year maintenance dosing schedule.

In June 2019, Alexion Received the US FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive.

Segment by Regions

 	
North America
 	
Europe
 	
China
 	
Japan